Unichem Laboratories Limited (IN:UNICHEMLAB)
:UNICHEMLAB
Want to see IN:UNICHEMLAB full AI Analyst Report?
UNICHEMLAB Stock Chart & Stats
₹443.05
-₹12.85(-1.76%)
At close: 4:00 PM EST
₹443.05
-₹12.85(-1.76%)
Day’s Range― - ―
52-Week Range₹280.00 - ₹668.00
Previous CloseN/A
Volume14.19K
Average Volume (3M)1.03K
Market Cap
₹26.35B
Enterprise Value₹29.66B
Total Cash (Recent Filing)₹1.94B
Total Debt (Recent Filing)₹5.02B
Price to Earnings (P/E)2.9
Beta1.21
Next Earnings
May 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)37.54
Shares Outstanding70,405,754
10 Day Avg. Volume1,013
30 Day Avg. Volume1,033
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)2.00
Price to Sales (P/S)2.32
P/FCF Ratio-33.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth TrendSustained revenue growth over multiple years indicates durable demand across Unichem's branded formulations, exports and API segments. A doubling of revenue in five years supports scale benefits, broader market penetration and a stronger base for future margin and cash generation improvements.
Improved Gross MarginA material improvement in gross margin to ~59% reflects better product mix, manufacturing efficiency or pricing power. Higher structural gross margins increase resilience to input cost swings and underpin long-term operating leverage as revenue grows, supporting sustainable profitability upside.
Low Leverage / Strong Equity BaseA rising equity base and low debt-to-equity ratio provide financial flexibility for R&D, regulatory filings and international rollouts. Low leverage reduces refinancing risk and preserves capacity for opportunistic M&A or capital expenditure without materially pressuring interest coverage or solvency metrics.
Bears Say
Negative Operating & Free Cash FlowNegative operating and free cash flow signal weak cash conversion despite revenue growth, creating structural funding pressure for working capital and capex. Persistent negative cash generation can force external financing, constrain reinvestment or slow international commercialization and API capacity builds.
Modest Net Profitability & Margin VolatilityA low net margin near 6.5% and volatile operating margins limit retained earnings and cushion for shocks. Structural modest profitability reduces reinvestment capacity and makes returns sensitive to pricing, regulatory or input-cost changes, undermining long-term predictable cash flows.
Slightly Falling Equity Ratio / Rising LiabilitiesA declining equity ratio, even if slight, indicates liabilities growing faster than assets and can erode financial flexibility over time. If the trend continues it could increase leverage risk, constrain borrowing capacity and raise funding costs for expansion or regulatory compliance investments.
Unichem Laboratories Limited News
UNICHEMLAB FAQ
What was Unichem Laboratories Limited’s price range in the past 12 months?
Unichem Laboratories Limited lowest stock price was ₹280.00 and its highest was ₹668.00 in the past 12 months.
What is Unichem Laboratories Limited’s market cap?
Unichem Laboratories Limited’s market cap is ₹26.35B.
When is Unichem Laboratories Limited’s upcoming earnings report date?
Unichem Laboratories Limited’s upcoming earnings report date is May 21, 2026 which is in 21 days.
How were Unichem Laboratories Limited’s earnings last quarter?
Unichem Laboratories Limited released its earnings results on Feb 05, 2026. The company reported ₹37.538 earnings per share for the quarter, beating the consensus estimate of N/A by ₹37.538.
Is Unichem Laboratories Limited overvalued?
According to Wall Street analysts Unichem Laboratories Limited’s price is currently Overvalued.
Does Unichem Laboratories Limited pay dividends?
Unichem Laboratories Limited pays a Annually dividend of ₹4 which represents an annual dividend yield of N/A. See more information on Unichem Laboratories Limited dividends here
What is Unichem Laboratories Limited’s EPS estimate?
Unichem Laboratories Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Unichem Laboratories Limited have?
Unichem Laboratories Limited has 70,405,754 shares outstanding.
What happened to Unichem Laboratories Limited’s price movement after its last earnings report?
Unichem Laboratories Limited reported an EPS of ₹37.538 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.969%.
Which hedge fund is a major shareholder of Unichem Laboratories Limited?
Currently, no hedge funds are holding shares in IN:UNICHEMLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Unichem Laboratories Limited
Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products worldwide. It offers formulation products that address various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infective, and pain management; and active pharmaceutical ingredients, as well as contract manufacturing services. The company was founded in 1944 and is headquartered in Mumbai, India.
Technical Analysis
Aarti Drugs Limited
―
Dishman Carbogen Amcis Ltd.
―
Gufic Biosciences Limited
―
RPG Life Sciences Limited
―
―